Literature DB >> 29397297

Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned.

Jeanette E Boudreau1, Katharine C Hsu2.   

Abstract

The functional capacities of natural killer (NK) cells differ within and between individuals, reflecting considerable genetic variation. 'Licensing/arming', 'disarming', and 'tuning' are models that have been proposed to explain how interactions between MHC class I molecules and their cognate inhibitory receptors - Ly49 in mice and KIR in humans - 'educate' NK cells for variable reactivity and sensitivity to inhibition. In this review we discuss recent progress toward understanding the genetic, epigenetic, and molecular features that titrate NK effector function and inhibition, and the impact of variable NK cell education on human health and disease.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29397297      PMCID： PMC6013060          DOI： 10.1016/j.it.2017.12.001

Source DB:  PubMed          Journal:  Trends Immunol        ISSN： 1471-4906            Impact factor:   16.687


  126 in total

1.  Expansion of a unique CD57⁺NKG2Chi natural killer cell subset during acute human cytomegalovirus infection.

Authors:  Sandra Lopez-Vergès; Jeffrey M Milush; Brian S Schwartz; Marcelo J Pando; Jessica Jarjoura; Vanessa A York; Jeffrey P Houchins; Steve Miller; Sang-Mo Kang; Phillip J Norris; Douglas F Nixon; Lewis L Lanier
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-08       Impact factor: 11.205

2.  Confinement of activating receptors at the plasma membrane controls natural killer cell tolerance.

Authors:  Sophie Guia; Baptiste N Jaeger; Stefan Piatek; Sébastien Mailfert; Tomasz Trombik; Aurore Fenis; Nicolas Chevrier; Thierry Walzer; Yann M Kerdiles; Didier Marguet; Eric Vivier; Sophie Ugolini
Journal:  Sci Signal       Date:  2011-04-05       Impact factor: 8.192

3.  Coordinated expression of DNAM-1 and LFA-1 in educated NK cells.

Authors:  Monika Enqvist; Eivind Heggernes Ask; Elin Forslund; Mattias Carlsten; Greger Abrahamsen; Vivien Béziat; Sandra Andersson; Marie Schaffer; Anne Spurkland; Yenan Bryceson; Björn Önfelt; Karl-Johan Malmberg
Journal:  J Immunol       Date:  2015-03-30       Impact factor: 5.422

4.  Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism.

Authors:  C M Gardiner; L A Guethlein; H G Shilling; M Pando; W H Carr; R Rajalingam; C Vilches; P Parham
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

5.  Differential Role of Hematopoietic and Nonhematopoietic Cell Types in the Regulation of NK Cell Tolerance and Responsiveness.

Authors:  Djem U Kissiov; Michele Ardolino; Nataliya Tovbis Shifrin; Nathalie T Joncker; David H Raulet
Journal:  J Immunol       Date:  2016-10-19       Impact factor: 5.422

6.  Immunoreceptor tyrosine-based inhibitory motif-dependent functions of an MHC class I-specific NK cell receptor.

Authors:  Michael D Bern; Diana L Beckman; Takashi Ebihara; Samantha M Taffner; Jennifer Poursine-Laurent; J Michael White; Wayne M Yokoyama
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-18       Impact factor: 11.205

7.  Common HIV-1 peptide variants mediate differential binding of KIR3DL1 to HLA-Bw4 molecules.

Authors:  Lena Fadda; Geraldine M O'Connor; Swati Kumar; Alicja Piechocka-Trocha; Clair M Gardiner; Mary Carrington; Daniel W McVicar; Marcus Altfeld
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

8.  Mutational and structural analysis of KIR3DL1 reveals a lineage-defining allotypic dimorphism that impacts both HLA and peptide sensitivity.

Authors:  Geraldine M O'Connor; Julian P Vivian; Jacqueline M Widjaja; John S Bridgeman; Emma Gostick; Bernard A P Lafont; Stephen K Anderson; David A Price; Andrew G Brooks; Jamie Rossjohn; Daniel W McVicar
Journal:  J Immunol       Date:  2014-02-21       Impact factor: 5.422

9.  KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma.

Authors:  Christopher J Forlenza; Jeanette E Boudreau; Junting Zheng; Jean-Benoît Le Luduec; Elizabeth Chamberlain; Glenn Heller; Nai-Kong V Cheung; Katharine C Hsu
Journal:  J Clin Oncol       Date:  2016-04-11       Impact factor: 44.544

10.  Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses.

Authors:  Silke Paust; Harvinder S Gill; Bao-Zhong Wang; Michael P Flynn; E Ashley Moseman; Balimkiz Senman; Marian Szczepanik; Amalio Telenti; Philip W Askenase; Richard W Compans; Ulrich H von Andrian
Journal:  Nat Immunol       Date:  2010-10-24       Impact factor: 25.606
View more
  64 in total

1.  Patrolling Monocytes Control NK Cell Expression of Activating and Stimulatory Receptors to Curtail Lung Metastases.

Authors:  Prakash Babu Narasimhan; Tobias Eggert; Yanfang Peipei Zhu; Paola Marcovecchio; Melissa A Meyer; Runpei Wu; Catherine C Hedrick
Journal:  J Immunol       Date:  2019-11-25       Impact factor: 5.422

Review 2.  Membrane Organization and Physical Regulation of Lymphocyte Antigen Receptors: A Biophysicist's Perspective.

Authors:  Laurent Limozin; Pierre-Henri Puech
Journal:  J Membr Biol       Date:  2019-07-27       Impact factor: 1.843

3.  Natural killer cells induce distinct modes of cancer cell death: Discrimination, quantification, and modulation of apoptosis, necrosis, and mixed forms.

Authors:  Christian S Backes; Kim S Friedmann; Sebastian Mang; Arne Knörck; Markus Hoth; Carsten Kummerow
Journal:  J Biol Chem       Date:  2018-09-06       Impact factor: 5.157

Review 4.  Killers 2.0: NK cell therapies at the forefront of cancer control.

Authors:  Jonathan J Hodgins; Sarwat T Khan; Maria M Park; Rebecca C Auer; Michele Ardolino
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

5.  Contribution of NK Cell Education to both Direct and Anti-HIV-1 Antibody-Dependent NK Cell Functions.

Authors:  Anne B Kristensen; Stephen J Kent; Matthew S Parsons
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

Review 6.  Natural killer cells in liver diseases.

Authors:  Meijuan Zheng; Haoyu Sun; Zhigang Tian
Journal:  Front Med       Date:  2018-04-19       Impact factor: 4.592

7.  Diversity of KIR, HLA Class I, and Their Interactions in Seven Populations of Sub-Saharan Africans.

Authors:  Neda Nemat-Gorgani; Lisbeth A Guethlein; Brenna M Henn; Steven J Norberg; Jacques Chiaroni; Martin Sikora; Lluis Quintana-Murci; Joanna L Mountain; Paul J Norman; Peter Parham
Journal:  J Immunol       Date:  2019-03-27       Impact factor: 5.422

Review 8.  True Detective: Unraveling Group 1 Innate Lymphocyte Heterogeneity.

Authors:  Luke Riggan; Aharon G Freud; Timothy E O'Sullivan
Journal:  Trends Immunol       Date:  2019-09-06       Impact factor: 16.687

9.  Report from the Killer-cell Immunoglobulin-like Receptors (KIR) component of the 17th International HLA and Immunogenetics Workshop.

Authors:  Maneesh K Misra; Danillo G Augusto; Gonzalo Montero Martin; Neda Nemat-Gorgani; Jürgen Sauter; Jan A Hofmann; James A Traherne; Betsy González-Quezada; Clara Gorodezky; Will P Bultitude; Wesley Marin; Cynthia Vierra-Green; Kirsten M Anderson; Antonio Balas; Jose L Caro-Oleas; Elisa Cisneros; Francesco Colucci; Ravi Dandekar; Sally M Elfishawi; Marcelo A Fernández-Viña; Merhan Fouda; Rafael González-Fernández; Arend Große; Maria J Herrero-Mata; Sam Q Hollenbach; Steven G E Marsh; Alex Mentzer; Derek Middleton; Ashley Moffett; Miguel A Moreno-Hidalgo; Ghada I Mossallam; Annettee Nakimuli; Jorge R Oksenberg; Stephen J Oppenheimer; Peter Parham; Maria-Luiza Petzl-Erler; Dolores Planelles; Florentino Sánchez-García; Francisco Sánchez-Gordo; Alexander H Schmidt; John Trowsdale; Luciana B Vargas; Jose L Vicario; Carlos Vilches; Paul J Norman; Jill A Hollenbach
Journal:  Hum Immunol       Date:  2018-10-12       Impact factor: 2.850

Review 10.  Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD.

Authors:  Bruce R Blazar; Geoffrey R Hill; William J Murphy
Journal:  Nat Rev Clin Oncol       Date:  2020-04-20       Impact factor: 66.675
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.